Combined treatment with Ad.5/3-mda-7 and BI-97C1 significantly enhanced toxicity in human prostate cancer cells, inhibited the growth of prostate cancer xenografts in vivo and controlled cancer development in a transgenic immune-competent mouse model of prostate cancer (Hi-Myc model) [112]. The gene discussed is MYC; the disease is prostate carcinoma.